PHVS retail attention spikes as options flip bullish

Retail attention on PHVS has hit 6.6 standard deviations above its 90-day average, per Wikipedia page views and ORTEX stock traffic as of October 19. That spike lands alongside an abrupt shift in options positioning and a borrow market that is opening up, three distinct signals converging on the same name within days of each other.

Options traders ditch the downside

The put-call ratio dropped to 0.79 on October 20, down from a 20-day mean of 1.77. That move is 3.5 standard deviations below the recent average, and it is the lowest reading in the data going back to a 52-week low of 0.0. For most of the past month, the PCR sat in a tight band between 1.83 and 1.92, a pattern that snapped sharply lower over the past two sessions. Traders are either closing put protection or adding calls at a pace that stands out against the stock's own history.

Borrow loosens as retail crowds in

The cost to borrow has fallen 55% over the past week to 0.56%, the lowest level in months. Availability now stands at 1,939%, up 65% week-on-week and well above the 52-week low of 178%. With nearly 14.4 million shares available against roughly 2.1 million shares short, the lending market is not a constraint here. Short interest itself sits at 3.2% of free float, little changed over the past month, and there is no borrow squeeze story to tell.

Analyst targets sit well above the current price

The stock trades at $30.90, down 15% over the past month. The mean analyst price target is $51.38, implying roughly 66% upside from current levels. Every recent analyst move from September has been an upgrade to target prices, not ratings: Morgan Stanley raised its target to $62, Leerink Partners to $65, Wells Fargo to $65, and RBC Capital to $62, all following what appeared to be clinical data. FMR (Fidelity) added 280,800 shares in the quarter ended September 30. Wellington Management added 1.16 million shares in the period ended August 31. Polar Capital added 1.55 million shares through June.

On the other side, a director sold $7 million worth of stock on September 17 in an open-market transaction. Net insider disposals over the past 90 days total roughly $20.4 million. Those were real-money sales at prices above $33, well above where the stock trades today.

What to watch

Pharvaris reports earnings on November 12. The stock has moved between minus 5% and plus 10% on the day across its four most recent prints. The options shift and the retail attention spike are both happening 22 days out from that date.

---

Data summary

• Retail attention z-score: 6.62 vs 90-day average (as of October 19)
• Put-call ratio: 0.79, z-score minus 3.5 vs 20-day mean of 1.77
• Cost to borrow: 0.56%, down 55% week-on-week
• Availability: 1,939%, up 65% week-on-week
• Short interest: 3.2% of free float
• Stock price: $30.90, down 15% over one month
• Mean analyst target: $51.38
• Net insider sales, 90 days: minus $20.4 million
• Next earnings: November 12